AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04646577 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Subjects will either undergo (1) active low-frequency rTMS (1Hz continuous) prime with anodal Transcranial Direct Current Stimulation (tDCS) on the affected side combine with Constraint induced movement therapy. Each session will last 20 minutes.
Study NCT00993304 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: In the first 3-week period, the treatment will be with placebo. Subsequently, a wash-out period of 3 to 9 weeks occurs and then a second period of one week with 0.6 mg, one week with 1.2 mg and one week with 1.8 mg of liraglutide. At the end of each of the 2 treatment periods, a high fat meal test will be performed.
Study NCT04646577 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS
Description: Subjects will either undergo sham Transcranial Direct Current Stimulation (tDCS) on the affected side combine with Constraint-induced movement therapy.
Study NCT04646577 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS
Description: Subjects will either undergo sham Transcranial Direct Current Stimulation (tDCS) on the affected side combine with Constraint-induced movement therapy.
Study NCT03595735 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zenflow Spring System
Description: The Zenflow Spring System consists of the Spring Delivery System with Implant, Spring Scope, Camera Control Unit (CCU), Measurement Tool, and Spring Retrieval Tool.
Study NCT01823380 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood test
Description: Blood test
Study NCT02235792 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activa PC+S
Description: The model 37604 Activa PC+S system is a multiprogrammable device that both delivers electrical stimulation and records bioelectric data through one or two leads implanted in the brain.
Study NCT00726128 — intervention group
Intervention type: DEVICE
Intervention: VueLock™ Anterior Cervical Plate
Description: Implanted in subjects having an ACDF (Anterior cervical discectomy and fusion)
Study NCT01840488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irosustat (BN83495)
Description: Three parts (A, B \& C) open label, multiple cohort, dose escalation study with once daily administration of irosustat at 1, 5, 20, 40 and 80 mg. Patients treated in any cohort were not allowed to escalate to higher doses or be enrolled in another dosing cohort.~Part A - Single oral daily dose for 7 days, Part B - Repeated oral daily dose for 28 days and Part C - Repeated oral daily administration until disease progression.
Study NCT03402932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auditory amplified
Description: The cognitive test will be administered using a computer-based signal processing to amplify the instruction. The presentation level is customized to the individual's hearing thresholds.
Study NCT03402932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual
Description: The cognitive test will be administered visually by using timed computer slides.
Study NCT03402932 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Visual
Description: The cognitive test will be administered visually by using timed computer slides.
Study NCT03402932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auditory unamplified
Description: The cognitive test will be administered by using a generic presentation level that simulates a normal conversational level.
Study NCT04406389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin sodium
Description: Intermediate Dose Prophylaxis Arm:~0.5 mg/kg subcutaneously every 12 hours if creatinine clearance greater than or equal to 30 ml/min --OR-- 0.5 mg/kg subcutaneously every 24 hours if creatinine clearance less than 30 ml/min~Therapeutic Dose Anticoagulation Arm:~1 mg/kg subcutaneously every 12 hours
Study NCT04406389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin sodium
Description: Intermediate Dose Prophylaxis Arm:~0.5 mg/kg subcutaneously every 12 hours if creatinine clearance greater than or equal to 30 ml/min --OR-- 0.5 mg/kg subcutaneously every 24 hours if creatinine clearance less than 30 ml/min~Therapeutic Dose Anticoagulation Arm:~1 mg/kg subcutaneously every 12 hours
Study NCT04406389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin
Description: Intermediate Dose Prophylaxis Arm:~7,500 units subcutaneously every 8 hours~Therapeutic Dose Anticoagulation Arm:~Dosed to target anti-Xa level 0.3 - 0.7 IU/mL or activated partial thromboplastin time (aPTT), according to institutional protocol
Study NCT04406389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Description: Intermediate Dose Prophylaxis Arm:~7,500 units subcutaneously every 8 hours~Therapeutic Dose Anticoagulation Arm:~Dosed to target anti-Xa level 0.3 - 0.7 IU/mL or activated partial thromboplastin time (aPTT), according to institutional protocol
Study NCT04406389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fondapariniux
Description: Intermediate Dose Prophylaxis Arm:~2.5 mg daily subcutaneously~Therapeutic Dose Anticoagulation Arm:~Dose by weight:~* If greater than or equal to 100 kg: 10 mg daily~* If less than 100 kg but greater than or equal to 50 kg: 7.5 mg daily~* If less than 50 kg: 5 mg daily
Study NCT04406389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fondapariniux
Description: Intermediate Dose Prophylaxis Arm:~2.5 mg daily subcutaneously~Therapeutic Dose Anticoagulation Arm:~Dose by weight:~* If greater than or equal to 100 kg: 10 mg daily~* If less than 100 kg but greater than or equal to 50 kg: 7.5 mg daily~* If less than 50 kg: 5 mg daily
Study NCT04406389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Argatroban
Description: Therapeutic Dose Anticoagulation Arm:~Dosed according to institutional protocol
Study NCT00145912 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI + CATCH-IT Internet Site
Description: MI + CATCH-IT Internet Site
Study NCT00145912 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BA (brief advice) + CATCH-IT Internet site
Description: BA (brief advice) + CATCH-IT Internet site
Study NCT02070874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telehealth enhanced pain management
Study NCT02931903 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vita Enamic (hybrid dental ceramic)
Description: Vita Enamic (hybrid dental ceramic) are provided as blocks to be milled using Computer aided design/Computer aided manufacturer (CAD/CAM) technology,
Study NCT02931903 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lithium disilicate glass-ceramic
Description: All ceramic crowns (Lithium disilicate glass ceramic) milled by Computer aided design/Computer aided manufacturer (CAD/CAM) technology
Study NCT01464034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg weekly PO or IV on Days 1, 8, 15, and 22, every 28 days.
Study NCT00675753 — intervention group
Intervention type: GENETIC
Intervention: Blood spot specimens will be drawn
Description: Blood spot specimens will be drawn from mother-baby dyads in the control and experimental groups and sent for genotyping
Study NCT01983709 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Human Mesenchymal Stem Cells
Description: This will be a dose escalation study. The first 3 subjects will receive a single dose of 1 x 10\^6 cells/kg or a maximum dose of 1 x 10\^8 total cells IV 4 days prior to undergoing a planned prostatectomy.~The remaining subjects will receive a single dose of 2 x 10\^6 cells/kg or a maximum dose of 2 x 10\^8 total cells IV either 4 or 6 days prior to the planned prostatectomy, and if additional doses of MSCs are able to be expanded, up to 6 additional men will be enrolled with a plan to treat them 8 days prior to the prostatectomy.
Study NCT02570516 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Description: A double colonoscopy is performed in a back-to-back design using NBI chromoendoscopy then indigo carmine in each patient.
Study NCT02570516 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: A double colonoscopy is performed in a back-to-back design using NBI chromoendoscopy then indigo carmine in each patient.
Study NCT04049617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evixapodlin
Description: Tablets administered orally.
Study NCT03293784 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Nivolumab+Ipilimumab in combination with Anti TNF-α Certolizumab
Description: Induction phase: Nivolumab (1mg/kg) and Ipilimumab (3 mg/kg) injected at Week 0, 3, 6, and 9 with Certolizumab injected at the dose of 400mg at weeks 0, 3, and 6, and at the dose of 200mg at week 9.~Maintenance phase: Nivolumab (3 mg/kg) alone injected from week 12 and then every 2 weeks with Certolizumab (200 mg) injected from week 12 and then every 2 weeks.
Study NCT03293784 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Nivolumab+Ipilimumab in combination with Anti TNF-α Infliximab
Description: Induction phase: Nivolumab (1mg/kg) and Ipilimumab 3 mg/kg injected at Week 0, 3, 6, and 9 with Infliximab (5mg/kg) injected at weeks 0, 3 and 6.~Maintenance phase: Nivolumab (3 mg/kg) alone injected from week 12 and then every 2 weeks with Infliximab (5mg/kg) injected from week 14 and then every 8 weeks.
Study NCT03908177 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ceramic Dental Implant
Description: The ceramic implant will be placed in healed extraction sockets in the premolar-to-premolar area in the mandible and maxilla for single tooth replacement followed by prosthetic loading after 4 months healing time. Type 4 surgery will be performed as defined by the ITI Consensus Statements for Implant Placement in Extraction Sockets: healed sites, typically around 16 weeks after tooth was extracted or after tooth was lost to allow complete healing of the ridge as well as soft- and hard tissue maturation. Both SG and CG receive routine treatment, only the choice of the implant material is defined by the study protocol.
Study NCT03908177 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Titanium Dental Implant
Description: The titanium implant will be placed in healed extraction sockets in the premolar-to-premolar area in the mandible and maxilla for single tooth replacement followed by prosthetic loading after 4 months healing time. Type 4 surgery will be performed as defined by the ITI Consensus Statements for Implant Placement in Extraction Sockets: healed sites, typically around 16 weeks after tooth was extracted or after tooth was lost to allow complete healing of the ridge as well as soft- and hard tissue maturation. Both SG and CG receive routine treatment, only the choice of the implant material is defined by the study protocol.
Study NCT02512926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed and refractory solid tumors and leukemias
Study NCT02512926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT02512926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study NCT03567382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate
Description: 300 mg tablet of TDF once daily from 28-32 weeks gestation through 12 weeks postpartum.
Study NCT03567382 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent HBV vaccine
Description: Infants born to HBsAg-positive women will be given a single dose of monovalent HBV vaccine within 24 hours of life.
Study NCT03853018 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CWAT intervention
Description: Participant in the intervention group will wear an activity tracker for 12 weeks.
Study NCT03853018 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CWAT + motivation intervention group
Description: Participant in the intervention group will wear an activity tracker for 12 weeks and are also motivated by the researcher via a lifestyle data platform.
Study NCT03236415 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience Drug Eluting Stent
Description: Patients will undergo insertion of a drug eluting stent with assessment of strut coverage using optical coherence tomography at 4 to 6 weeks after implantation.
Study NCT03236415 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ABSORB Bioresorbable Vascular Scaffold
Description: Patients will undergo insertion of a bioresorbable vascular scaffold with assessment of strut coverage using optical coherence tomography at 4 to 6 weeks after implantation.
Study NCT00856219 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Enteral Continuous
Description: Continuous Tube Feeding for 72 hours
Study NCT00856219 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Enteral Intermittent
Description: Intermittent Tube Feedings
Study NCT00856219 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Parenteral Continuous
Description: Parenteral Continuously for 72 hours
Study NCT03712982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention to Variability - Patient Only
Description: In Attention to Variability we ask the participant to attend to the natural fluctuations in mood and physiology that occur throughout the day, to notice when a symptom is better or worse and to ask why it may be.
Study NCT03712982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention to Variability - Partner Only
Description: In Attention to Variability we ask the participant to attend to the natural fluctuations in mood and physiology in their partner that occur throughout the day, to notice when a symptom is better or worse and to ask why it may be.
Study NCT03712982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention to Variability - Patient & Partner
Description: Same as patient and partner only conditions, just that in this condition both the patient and partner do their corresponding intervention rather than only one of them.
Study NCT03712982 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infertility Stories - Reading
Description: Reading Stories About Others' Infertility Experiences
Study NCT01517659 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Zeltiq CoolSculpting System
Description: Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
Study NCT01825889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Study NCT01219413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren, Perindopril
Description: Rasilez 300 mg Prestarium 10 mg
Study NCT04252898 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Front-of-pack nutrition label Nutri-Score
Description: The intervention consists of displaying the Nutri-Score on dishes and pre-packed foods.
Study NCT03996642 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Avatar Life Review
Description: VoicingHan will screen-capture patient's storytelling performances as video files. Immediately before the first intervention, patients will complete an array of self-reported questionnaires to assess physical, spiritual, and psychological well-being and elicit relevant demographic and medical information. The assessments include the ESAS, FACIT-Sp subscale, and EORTC PAL 15. Subsequent administration of these questionnaires spaced 2-4 weeks apart will occur before each avatar session (pre-intervention). This will determine if intensity of the patient's symptoms have changed over the course of the intervention. Following completion of the Avatar session, a member of the research team will conduct a semi-structured, open-ended interview to assess patients' perception of intervention components and identify possible factors influencing intervention feasibility and any technical barriers.
Study NCT04060719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894416
Description: tablet
Study NCT00241878 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teacher-Delivered Weight Control Intervention
Description: The teacher-delivered weight control intervention (TD-WCI) is implemented over 14 weeks with three lessons per week. Many lessons include the use of colorful, friendly, hand-made puppets that represent the seven food groups of the food pyramid (Miss Grain, Miss Fruit, Mr. Vegetable, Mr. Protein, Miss Dairy, Mr. Fat and Miss Sugar). Please see Appendix IX for complete curriculum and pictures of puppets. There are three 40-minute lessons per week that consist of a 15-20 minutes interactive healthy eating and exercise didactic session and then 20 minutes of ongoing physical activity (5 minutes warm-up, 15 minutes aerobic activity composed of a number of games and dances with music, 5 minutes cool-down). In addition to the child-based curriculum the WCI has parent newsletters. These newsletters are distributed on a weekly basis and provide information that parallels the children's curriculum
Study NCT00241878 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Teacher-Delivered General Health Intervention
Description: The teacher-delivered general health intervention (TD-GHI) serves as the control group in the proposed study. TD-GHI is a general health intervention that is similar in structure and length to TD-WCI. Topics include those related to general health and safety, such as car safety, being a good friend, poison safety, disease prevention, etc. An example of an activity is the 911 emergency call. The children learn what 911 is and what would be an appropriate call. They then practice calling 911 on play telephones and relating the important information: nature of the emergency, their name, their address, etc. They learn also to stay on the phone with the 911 dispatcher until someone comes to help them. In addition to the child-based curriculum the GHI has parent newsletters. Like TD-WCI these newsletters are distributed on a weekly basis and provide information that parallels the children's curriculum
Study NCT04060719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: tablet
Study NCT05177874 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Traumacel FAM Trium
Description: Absorbable Hemostat (oxidized non-regenerated cellulose)
Study NCT05177874 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgicel Fibrillar
Description: Absorbable Hemostat (oxidized regenerated cellulose)
Study NCT01021358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Subjects will be dosed with ABT-263, then dosed with ABT-263 in combination with Ketoconazole.
Study NCT01021358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Subjects will be dosed with ABT-263, then dosed with ABT-263 in combination with Ketoconazole.
Study NCT02337686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03402932 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Auditory unamplified
Description: The cognitive test will be administered by using a generic presentation level that simulates a normal conversational level.
Study NCT02337686 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT02337686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00567866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: 50 or 100 mg of quetiapine orally
Study NCT02337686 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT01743612 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser speckle contrast imaging
Description: blood flow recording during 30 minutes after 2 post-occlusive hyperaemia of 5 minutes separated by 30 minutes.
Study NCT01743612 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cooling
Description: blood flow of the hand recording during 30 minutes in a cooling-box
Study NCT01964378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cebranopadol
Description: Participant will take one or two tablet(s) of cebranopadol in the morning and one or two placebo double-dummy morphine-like capsule(s) in the morning and the evening.
Study NCT01964378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Prolonged Release
Description: Participant will take one or two morphine capsule(s) in the morning and in the evening and one or two placebo double-dummy cebranopadol-like tablet(s) in the morning.
Study NCT01619761 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic umbilical cord blood transplant
Study NCT01619761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT01619761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT01619761 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01619761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT01619761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT01619761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV or PO